Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.

Elías I, Oyagüez I, Alvarez-Sala LA, García-Bragado F, Navarro A, González P, De Andrés-Nogales F, Soto J.

Farm Hosp. 2016 May 1;40(n03):187-208.

2.

Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.

Elías I, Ortega-Joaquín N, de la Cueva P, Del Pozo LJ, Moreno-Ramírez D, Boada A, Aguilar M, Mirada A, Mosquera E, Gibbons C, Oyagüez I.

Actas Dermosifiliogr. 2016 Jul-Aug;107(6):498-508. doi: 10.1016/j.ad.2016.03.004. Epub 2016 Apr 26. English, Spanish.

PMID:
27130804
3.

Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.

Sabater E, López-Guillermo A, Rueda A, Salar A, Oyagüez I, Collar JM.

Appl Health Econ Health Policy. 2016 Aug;14(4):465-77. doi: 10.1007/s40258-016-0243-4.

PMID:
27090915
4.

[Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].

Buti M, Domínguez-Hernández R, Oyagüez I, Casado MÁ.

Gastroenterol Hepatol. 2016 Aug-Sep;39(7):449-57. doi: 10.1016/j.gastrohep.2016.03.006. Epub 2016 Apr 12. Spanish.

PMID:
27084669
5.

Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.

Quintero J, Oyagüez I, González B, Cuervo-Arango I, García I, Casado MA.

Clin Drug Investig. 2016 Jun;36(6):479-90. doi: 10.1007/s40261-016-0393-z.

PMID:
27000061
6.

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.

Rodríguez González-Moro JM, Menéndez R, Campins M, Lwoff N, Oyagüez I, Echave M, Rejas J, Antoñanzas F.

Clin Drug Investig. 2016 Jan;36(1):41-53. doi: 10.1007/s40261-015-0345-z.

7.

Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In Spain.

Almodóvar R, Gonzalez CM, Caloto T, Elías I, Oyagüez I, Tencer T.

Value Health. 2015 Nov;18(7):A646. doi: 10.1016/j.jval.2015.09.2313. Epub 2015 Oct 20. No abstract available.

PMID:
26533622
8.

Cost-Effectiveness Of A 13-Valent Conjugate Pneumococcal Vaccination Program In Copd Patients Aged 50+ Years In Spain.

Rodríguez-GonzálezMoro JM, Menendez R, Campins M, Lwoff N, Oyagüez I, Echave M, Rejas J, Antoñanzas F.

Value Health. 2015 Nov;18(7):A502. doi: 10.1016/j.jval.2015.09.1424. Epub 2015 Oct 20. No abstract available.

PMID:
26532817
9.

Cost-Effectiveness Of Tiotropium In The Treatment Of Patients With Asthma.

Echave M, Ojanguren ME, Elías I, de Andrés-Nogales F, Oyagüez I, Casado M, Crespo C.

Value Health. 2015 Nov;18(7):A501-2. doi: 10.1016/j.jval.2015.09.1420. Epub 2015 Oct 20. No abstract available.

PMID:
26532813
10.

Aflibercept in Combination with Folfiri in Patients with Metastatic Colorectal Cancer: Cost-Effectiveness Based on Velour Best Efficacy Subgroup Post-Hoc Analysis.

Echave M, Oyagüez I, Lamas MJ, Rubio M, Subirà R.

Value Health. 2015 Nov;18(7):A454. doi: 10.1016/j.jval.2015.09.1153. Epub 2015 Oct 20. No abstract available.

PMID:
26532551
11.

Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% for Actinic Keratosis Treatment In Spain.

Elias I, Ortega-Joaquin N, Aguilar M, Moreno D, Boada A, Del Pozo LJ, de la Cueva P, Mirada A, Mosquera E, Gibbons C, Oyagüez I.

Value Health. 2015 Nov;18(7):A423-4. doi: 10.1016/j.jval.2015.09.573. Epub 2015 Oct 20. No abstract available.

PMID:
26532387
12.

Cost-Utility Analysis of Ingenol Mebutate Versus Imiquimod 5% for Actinic Keratosis Treatment In Spain.

Ortega-Joaquin N, Elías I, de la Cueva P, Del Pozo LJ, Boada A, Moreno D, Aguilar M, Mosquera E, Mirada A, Gibbons C, Oyagüez I.

Value Health. 2015 Nov;18(7):A423. doi: 10.1016/j.jval.2015.09.569. Epub 2015 Oct 20. No abstract available.

PMID:
26532384
13.

Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain.

Carrascosa JM, Vanaclocha F, Caloto T, Echave M, Oyagüez I, Tencer T.

Value Health. 2015 Nov;18(7):A420. doi: 10.1016/j.jval.2015.09.555. Epub 2015 Oct 20. No abstract available.

PMID:
26532369
14.

Costs Analysis Of Pcr Unyverotm I60-Iti Technique For Detecting Microorganisms In Patients With Suspected Chronic Infection At Musculoskeletal Implants.

Torres C, Oyagüez I, Prieto L, Rodriguez G, Esteban J.

Value Health. 2015 Nov;18(7):A351. doi: 10.1016/j.jval.2015.09.642. Epub 2015 Oct 20. No abstract available.

PMID:
26531985
15.

Surgical Treatment of Pressure Ulcers with a Fibrin Sealant in Patients with Spinal Cord Injury: A Cost-Consequence Analysis.

Velasco JM, Lozano V, Oyagüez I, Casado MA.

Adv Skin Wound Care. 2015 Nov;28(11):503-7. doi: 10.1097/01.ASW.0000471875.06135.a1.

PMID:
26479693
16.

Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.

Jiménez-Ruiz CA, Solano-Reina S, Signes-Costa J, de Higes-Martinez E, Granda-Orive JI, Lorza-Blasco JJ, Riesco-Miranda JA, Altet-Gomez N, Barrueco M, Oyagüez I, Rejas J; SESEPARAR’s Integrated Tobacco Research Program.

Int J Chron Obstruct Pulmon Dis. 2015 Sep 24;10:2027-36. doi: 10.2147/COPD.S87597. eCollection 2015.

17.

Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.

Roncero C, Domínguez-Hernández R, Díaz T, Fernández JM, Forcada R, Martínez JM, Seijo P, Terán A, Oyagüez I.

Adicciones. 2015 Sep 15;27(3):179-89. English, Spanish.

18.

Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight.

Román Ivorra JA, Ivorra J, Monte-Boquet E, Canal C, Oyagüez I, Gómez-Barrera M.

Reumatol Clin. 2016 May-Jun;12(3):123-129. doi: 10.1016/j.reuma.2015.07.008. Epub 2015 Sep 9. English, Spanish.

19.

Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.

Gros B, Galán A, González-Parra E, Herrero JA, Echave M, Vegter S, Tolley K, Oyagüez I.

Health Econ Rev. 2015 Dec;5(1):49. doi: 10.1186/s13561-015-0049-3. Epub 2015 Jun 11.

20.

[Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].

De Lossada A, Oteo-Álvaro Á, Giménez S, Oyagüez I, Rejas J.

Semergen. 2016 May-Jun;42(4):235-43. doi: 10.1016/j.semerg.2015.04.008. Epub 2015 May 23. Spanish.

PMID:
26006311
Items per page

Supplemental Content

Loading ...
Write to the Help Desk